In extensive-stage small cell lung cancer, Ifinatamab deruxtecan’s BLA was voluntarily withdrawn for previously treated patients. The move signals an early retreat from development in that population after regulatory review pathways were pursued. For investors and pipeline planners, the withdrawal highlights the continued difficulty of delivering consistent efficacy signals for antibody-drug conjugates in SCLC, where response durability and safety windows remain central. The action also reshapes competitive dynamics among ADC and next-generation payload platforms targeting SCLC and adjacent lung indications.